KLK3 and Familial prostate cancer: Serum prostate specific antigen (PSA) has been widely used as the optimal conventional serum marker for prostate cancer in the clinical setting, especially as a marker for initial diagnosis, as it can predict cancer risk and treatment outcome [6].